Previous 10 | Next 10 |
JERSEY CITY, N.J. , June 5, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that a total of nine presentations revealing data which further d...
JERSEY CITY, N.J. , May 30, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the company has completed the nonclinical toxicology evaluations ...
SCYNEXIS (NASDAQ: SCYX ): Q1 GAAP EPS of -$0.46 misses by $0.26 . More news on: SCYNEXIS, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERSEY CITY, N.J. , May 8, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended March 31, 2019 , and pr...
Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...
JERSEY CITY, N.J. , May 6, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential of ibrexafungerp as an agent to address VVC...
JERSEY CITY, N.J. , May 1, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data further demonstrating the potential for ibrexafungerp to trea...
JERSEY CITY, N.J. , April 15, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced results showing evidence of activity of the company's lead product c...
WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinica...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +25% on out-licenses sarcopenia candidate PB1023. More news on: PhaseBio Pharmaceuticals, Inc., Cerner Corporation, SCYNEXIS, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...